Key Takeaway: Sanofi has released information regarding the total number of voting rights and shares as of February 29, 2024, in compliance with French regulations. The company reported a total of 1,264,891,324 issued shares and 1,406,985,229 real voting rights, which suggests a robust governance structure. This data aims to enhance transparency for investors and shareholders in the French market.
Price reaction · baseline $48.09 (2024-03-14 close) · hit after-hours · clean, no other SNY news in the window
day 0 close
+0.4%
Market Sentiment Analysis
POSITIVE FACTORS
Sanofi shows transparency by providing detailed voting rights information.
The total number of issued shares demonstrates a stable capital structure.
Real voting rights indicate shareholder engagement and confidence.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
teplizumab/mL
Phase 2 · Diabetes Mellitus, Type 1
Full Press Release Details
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
a French société anonyme with a registered share capital of 2,529,599,938 €
Registered office : 46, avenue de la Grande Armée - 75017 Paris - France
Registered at the Paris Commercial and Companies Registry under number 395 030 844
Date
Total number of issued shares
Number of real voting rights (excluding treasury shares)
Theoretical number of voting rights (including treasury shares)*
February 29, 2024
1,264,891,324
1,406,985,229
1,423,651,077
* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.
This information is also available on the internet website of sanofi under « Regulated Information in France »: